PT  - JOURNAL ARTICLE
AU  - Douglas, Jordan
AU  - Mendes, Fábio K.
AU  - Bouckaert, Remco
AU  - Xie, Dong
AU  - Jiménez-Silva, Cinthy L.
AU  - Swanepoel, Christiaan
AU  - Ligt, Joep de
AU  - Ren, Xiaoyun
AU  - Storey, Matt
AU  - Hadfield, James
AU  - Simpson, Colin R.
AU  - Geoghegan, Jemma L.
AU  - Drummond, Alexei J.
AU  - Welch, David
TI  - Phylodynamics reveals the role of human travel and contact tracing in controlling the first wave of COVID-19 in four island nations
AID  - 10.1101/2020.08.04.20168518
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.08.04.20168518
4099  - http://medrxiv.org/content/early/2021/02/24/2020.08.04.20168518.short
4100  - http://medrxiv.org/content/early/2021/02/24/2020.08.04.20168518.full
AB  - Background New Zealand, Australia, Iceland, and Taiwan all saw success at controlling the first wave of the COVID-19 pandemic. As islands, they make excellent case studies for exploring the effects of international travel and human movement on the spread of COVID-19.Methods We employed a range of robust phylodynamic methods and genome subsampling strategies to infer the epidemiological history of SARS-CoV-2 in these four countries. We compared these results to transmission clusters identified by the New Zealand Ministry of Health by contract tracing strategies.Findings We estimated the effective reproduction number of COVID-19 as 1–1.4 during early stages of the pandemic, and show that it declined below 1 as human movement was restricted. We also showed that this disease was introduced many times into each country, and that introductions slowed down markedly following the reduction of international travel in mid March 2020. Finally, we confirmed that New Zealand transmission clusters identified via standard health surveillance strategies largely agree with those defined by genomic data.Interpretation We have demonstrated how the use of genomic data and computational biology methods can assist health officials in characterising the epidemiology of viral epidemics, and for contact tracing.Funding This research was funded by the Health Research Council of New Zealand, the Ministry of Business, Innovation, and Employment, the Royal Society of New Zealand, and the New Zealand Ministry of Health.Evidence before this study Our study looks at the early months of the COVID-19 pandemic, a period in which the first wave was controlled in four “island” nations – New Zealand, Australia, Taiwan, and Iceland. All prior data used in this study was collected from late 2019 until the end of April 2020. This includes over 3000 SARS-CoV-2 genomic sequences which were collected in this period (and subsequently deposited into GISAID), as well as arrival and departure information (provided by official statistics from each country), human mobility data collected from mobile phones (by Apple), and COVID-19 case data (released by the World Health Organisation). Even early on during the COVID-19 pandemic, the properties of SARS-CoV-2 – including the reproduction number and mutation rate – were well characterised, and a range of these estimates have been covered in our article. Our Bayesian phylodynamic models, including their prior distributions, are informed by all of the above sources of information. Finally, we have incorporated all of the available information on COVID-19 transmission clusters identified by the New Zealand Ministry of Health during this period.Added value of this study We quantified the decline in the reproduction number of SARS-CoV-2, following the decline in human mobility, in four “island” countries. We also demonstrated how importation events of SARS-CoV-2 into each considered country declined markedly following the reduction of international travel. Our results shed a different light on these patterns because of (i) our locations of choice – the four countries had success in dealing with the first pandemic wave, with their geographic isolation contributing to cleaner signals of human mobility, and (ii) our novel and empirically driven phylodynamic model, which we built from explicitly modelling mobile phone data in the four islands. Furthermore, by crossing epidemiological against ge3nomic data, our paper quantitatively assesses the ability of contact tracing, as implemented by the New Zealand Ministry of Health (NZMH), in identifying COVID-19 transmission clusters. We find evidence for a high efficacy of the specific measures taken – and when they were taken – by the NZMH in identifying transmission clusters, considered worldwide to have been successful in its response to the pandemic. Our analyses also illustrate the power of viral genomic data in assisting contact tracing.Implications of all the available evidence The conclusions drawn from this research inform effective policy for locations pursuing an elimination strategy. We confirm the accuracy of standard contact tracing methods at identifying clusters and show how these methods are improved using genomic data. We demonstrate how the overseas introduction rates and domestic transmission rates of an infectious viral agent can be surveilled using genomic data, and the important role each plays in overall transmission. Specifically, we have quantified these processes for four countries and have shown that they did decline significantly following declines in human travel and mobility. The phylodynamic methods used in this work is shown to be robust and applicable to a range of scenarios where appropriate subsampling is used.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe wish to thank all of the authors who have shared their genomic data on GISAID. A full table outlining the originating and submitting labs is included as a supplementary file. This research was supported by a contract from the Health Research Council of New Zealand (20/1018), a COVID-19 Innovation Acceleration Fund (grant CIAF-0470) from the Ministry of Business, Innovation & Employment’s Research Infrastructure (MBIE), and Marsden grants 16-UOA-277 and 18-UOA-096 from the Royal Society of New Zealand. Genome sequencing was partially funded by New Zealand Ministry of Health. Finally, we wish to acknowledge the use of New Zealand eScience Infrastructure (NeSI) high performance computing facilities, funded jointly by NeSI's collaborator institutions and through the MBIE's Research Infrastructure program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The genomic data was obtained by the Institute of Environmental Science and Research (ESR). Under contract of the Ministry of Health New Zealand, ESR holds ethical approval to conduct genomic sequencing for disease surveillance.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon publication